Journal Articles

Permanent URI for this collectionhttps://mro.massey.ac.nz/handle/10179/7915

Browse

Filters

20252

Settings

Author: search.filters.author.Hill KESubject: search.filters.subject.Cat Diseases

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Effects of intranasal maropitant on clinical signs of naturally acquired upper respiratory disease in shelter cats
    (SAGE Publications on behalf of the nternational Cat Care Veterinary Society and Feline Veterinary Medical Association, 2025-02-26) Parncutt J; Johnson LR; Subharat S; Oke B; Hill KE
    OBJECTIVES: The aim of this study was to test the hypothesis that intranasally administered maropitant citrate would reduce the severity of clinical signs of feline upper respiratory disease (FURD) in shelter cats with naturally acquired disease. METHODS: Shelter cats with clinical signs of FURD were randomly assigned to receive either intranasal maropitant diluted in saline (maropitant citrate 10 mg/ml q12h, diluted 1:10 with sterile 0.9% saline) or intranasal 0.9% saline q12h for 7 days. Clinical disease severity was measured at entry into the study and again after completion of 7 days of treatment using a visual analogue scale to assess four separate clinical signs: conjunctivitis, blepharospasm, ocular discharge and nasal discharge. Total disease severity was also calculated. Cats received other medications for FURD as per standard shelter protocols, and all investigators were masked to group assignments. A Mann-Whitney U-test was performed to compare the clinical improvement score (CIS) between the treatment and control groups. RESULTS: There were 34 cats in the maropitant treatment group; 27 cats served as placebo controls. Groups did not differ in age, sex distribution, nature of disease, administration of other medications for FURD or baseline clinical disease severity. There was no significant difference in CIS between the maropitant treatment and control groups for conjunctivitis, blepharospasm, ocular discharge, nasal discharge or total disease severity after 7 days. CONCLUSIONS AND RELEVANCE: This study found no significant difference in outcomes for cats with FURD when treated with intranasal maropitant compared with treatment with intranasal saline. Further investigations would be required before intranasal maropitant could be recommended as the standard of care for FURD.
  • Thumbnail Image
    Item
    Medication compliance by cat owners prescribed treatment for home administration.
    (Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine., 2025-01-11) Odom TF; Riley CB; Benschop J; Hill KE
    BACKGROUND: Most veterinary literature examining medication compliance has described the phenomenon in dogs. The evidence available regarding factors affecting cat owner medication compliance is limited. OBJECTIVES: Identify and describe factors associated with cat owners' noncompliance with veterinary recommendations for pet medications, as well as client-reported barriers and aids to administering medications prescribed by primary care veterinarians. SUBJECTS: Cat owners presenting their animals for veterinary examination and treatment. METHODS: A cross-sectional survey of cat owners' compliance with veterinary medication recommendations was performed from January 9, 2019, to July 18, 2020. A convenience sample of owners prescribed medication for their pets by veterinarians during or after elective veterinary examination was recruited to respond to questions regarding medication administration experience and compliance. Follow-up was obtained from owners to determine if the course of medication had been completed. Compliance data were analyzed descriptively, and logistic regression was performed. RESULTS: Medication noncompliance was recorded for 39% (26/66) of cat owners. A quarter (16/66) reported challenges in administering medication to their pets; the most commonly cited reason was a resistant pet. Oral administration of antibiotics was significantly associated with noncompliance (P = .01). Clients with limited pet ownership experience were less likely to be noncompliant (P = .04). CONCLUSIONS AND CLINICAL IMPORTANCE: Clients' inability to medicate their cats PO may have implications for clinical outcomes and antimicrobial stewardship. Alternatives to direct PO administration of solid-form medications in cats should be considered. Demonstrating administration techniques to all clients may improve compliance and influence clinical outcome.